Unnamed: 0,title,date,stock,sentiment
106840.0,"The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas",2020-05-27 07:25:00-04:00,ATRA,positive
106841.0,Atara Biotherapeutics Prices 12.6M Share Public Offering @$11.32/Share,2020-05-27 05:44:00-04:00,ATRA,positive
106842.0,96 Biggest Movers From Yesterday,2020-05-27 04:20:00-04:00,ATRA,neutral
106843.0,Atara Biotherapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants; No Terms Disclosed,2020-05-26 16:09:00-04:00,ATRA,negative
106844.0,61 Stocks Moving In Tuesday's Mid-Day Session,2020-05-26 12:29:00-04:00,ATRA,neutral
106845.0,Atara Biotherapeutics Presents Data Demonstrating Safety & Sustained Disability Improvement at 12 Months With ATA188 In Patients With Progressive Multiple Sclerosis In Late-Breaking e-Poster At 2020 European Academy Of Neurology Virtual Congress,2020-05-26 07:07:00-04:00,ATRA,positive
106846.0,"The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray",2020-05-22 07:10:00-04:00,ATRA,neutral
106847.0,70 Biggest Movers From Yesterday,2020-05-21 05:22:00-04:00,ATRA,neutral
106848.0,"Shares of several healthcare companies are trading higher in sympathy with the overall market amid strength in oil, strong earnings from Lowe's and optimism towards a US economic rebound.",2020-05-20 11:19:00-04:00,ATRA,positive
106849.0,Atara Biotherapeutics Highlights Will Present Late-Breaking ATA188 Data In Progressive Multiple Sclerosis At European Academy Of Neurology Virtual Congress,2020-05-19 08:33:00-04:00,ATRA,neutral
106850.0,"JP Morgan Maintains Neutral on Atara Biotherapeutics, Raises Price Target to $23",2020-05-12 10:35:00-04:00,ATRA,positive
106851.0,"The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle",2020-05-06 08:42:00-04:00,ATRA,positive
106852.0,Atara Biotherapeutics shares are trading higher after Citigroup upgraded the stock from Neutral to Buy.,2020-04-23 08:14:00-04:00,ATRA,positive
106853.0,Citigroup Upgrades Atara Biotherapeutics to Buy,2020-04-23 05:10:00-04:00,ATRA,neutral
106854.0,56 Stocks Moving In Tuesday's Mid-Day Session,2020-04-07 12:47:00-04:00,ATRA,neutral
106855.0,Atara Biotherapeutics Says Remains On Track To Initiate tab-cel Biologics License Aplpication Submission For Patients With EBV+ PTLD In H2'20,2020-04-02 08:41:00-04:00,ATRA,neutral
106856.0,"The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates",2020-03-18 07:36:00-04:00,ATRA,positive
106857.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-12 12:10:00-04:00,ATRA,negative
106858.0,"The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO",2020-03-12 07:37:00-04:00,ATRA,negative
106859.0,"The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment",2020-03-11 08:03:00-04:00,ATRA,positive
106860.0,"The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO",2020-02-28 07:28:00-05:00,ATRA,neutral
106861.0,Stocks That Hit 52-Week Lows On Thursday,2020-02-27 10:23:00-05:00,ATRA,negative
106862.0,Atara Biotherapeutics Q4 EPS $(1.36) Misses $(1.34) Estimate,2020-02-27 08:58:00-05:00,ATRA,negative
106863.0,Atara Bio Filing Shows Registration For $100M Common Stock Offering,2020-02-27 08:52:00-05:00,ATRA,neutral
106864.0,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy",2020-02-27 07:35:00-05:00,ATRA,positive
106865.0,The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace,2020-02-23 18:38:00-05:00,ATRA,neutral
106866.0,"Atara Biotherapeutics to Present 2020 Key Milestones and Progress in Bringing Off-The-Shelf, Allogeneic T-Cell Immunotherapies to Patients in Need at the 38th Annual J.P. Morgan Healthcare Conference",2020-01-12 14:51:00-05:00,ATRA,positive
106867.0,"Benzinga's Top Upgrades, Downgrades For November 8, 2019",2019-11-08 09:33:00-05:00,ATRA,positive
106868.0,"JP Morgan Downgrades Atara Biotherapeutics to Neutral, Lowers Price Target to $22",2019-11-08 06:14:00-05:00,ATRA,positive
106869.0,Atara Biotherapeutics Earlier Reported Q3 EPS $(1.31) Beats $(1.44) Estimate,2019-11-07 09:35:00-05:00,ATRA,neutral
106870.0,"The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs",2019-11-07 07:18:00-05:00,ATRA,negative
106871.0,"The Daily Biotech Pulse: Agile Receives Favorable Adcom Verdict, Merit Medical Tumbles On Earnings, 2 Biotechs To Debut",2019-10-31 08:08:00-04:00,ATRA,positive
106872.0,Stocks That Hit 52-Week Lows On Wednesday,2019-10-30 10:38:00-04:00,ATRA,negative
106873.0,"The Daily Biotech Pulse: Novartis Program Placed On Partial Clinical Hold, Adcom Snub For Amag, Amgen Earnings",2019-10-30 07:01:00-04:00,ATRA,negative
106874.0,Atara Biotherapeutics Chief Science Officer Reportedly Has Left Co.,2019-10-25 14:07:00-04:00,ATRA,neutral
106875.0,64 Biggest Movers From Yesterday,2019-10-15 05:07:00-04:00,ATRA,neutral
106876.0,"Benzinga's Top Upgrades, Downgrades For September 27, 2019",2019-09-27 09:39:00-04:00,ATRA,positive
106877.0,21 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-09-27 08:45:00-04:00,ATRA,neutral
106878.0,Atara Biotherapeutics shares are trading lower after Goldman Sachs downgraded the stock from Neutral to Sell and lowered the price target from $14 to $9 per share.,2019-09-27 08:34:00-04:00,ATRA,positive
106879.0,25 Stocks Moving in Friday's Pre-Market Session,2019-09-27 08:27:00-04:00,ATRA,neutral
106880.0,"Goldman Sachs Downgrades Atara Biotherapeutics to Sell, Lowers Price Target to $9",2019-09-27 06:13:00-04:00,ATRA,negative
106881.0,"Benzinga's Top Upgrades, Downgrades For September 16, 2019",2019-09-16 10:17:00-04:00,ATRA,positive
106882.0,10 Biggest Price Target Changes For Monday,2019-09-16 08:49:00-04:00,ATRA,neutral
106883.0,"Jefferies Downgrades Atara Biotherapeutics to Hold, Lowers Price Target to $15",2019-09-16 06:53:00-04:00,ATRA,negative
106884.0,"The Daily Biotech Pulse: All Eyes On Aimmune, Ritter Stumbles In Late-Stage Study, Catalyst Shelves Offering Plans",2019-09-13 07:40:00-04:00,ATRA,neutral
106885.0,Atara Biotherapeutics Reports Early Findings Of Potential Efficacy From Phase 1 Study Of ATA188 In Patients With Progressive Multiple Sclerosis At ECTRIMS,2019-09-13 06:16:00-04:00,ATRA,neutral
106886.0,"Canaccord Maintains Buy, $70 Tgt On Atara Biotherapeutics Ahead Of 'preliminary efficacy data at ECTRIMS on Friday, 9/13, in n=12 patients at 6 months of follow-up and will discuss changes in EDSS score, a key endpoint for progressive multiple sclerosis'",2019-09-11 12:05:00-04:00,ATRA,neutral
106887.0,"The Daily Biotech Pulse: Lexicon Snaps Sanofi Diabetes Partnership With $260M Settlement, Celyad Offering, Multiple Sclerosis Conference Gets Underway",2019-09-11 07:09:00-04:00,ATRA,neutral
106888.0,"The Week Ahead In Biotech: Conference Presentations, IPO News Flow Take The Spotlight",2019-09-08 11:01:00-04:00,ATRA,neutral
106889.0,Shares of several healthcare companies are trading higher in sympathy with the overall market after the Chinese Minister of Commerce said the leaders of the U.S. and China are set to meet in Washington D.C in early October. Investors hope the meeting could bring the two countries closer to a trade deal.,2019-09-05 15:34:00-04:00,ATRA,positive
106890.0,Atara Biotherapeutics Earlier Reported Q2 EPS $(1.6) Misses $(1.5) Estimate,2019-08-08 10:39:00-04:00,ATRA,negative
106891.0,Stocks That Fell Through 52-Week Lows Wednesday,2019-08-07 14:22:00-04:00,ATRA,negative
106892.0,"The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering",2019-08-06 07:22:00-04:00,ATRA,positive
106893.0,New 52-Week Lows For Monday Morning,2019-08-05 13:16:00-04:00,ATRA,negative
106894.0,Stocks That Set New 52-Week Lows Friday Morning,2019-08-02 10:46:00-04:00,ATRA,negative
106895.0,Stocks that Reached Yearly Lows Thursday Morning,2019-08-01 11:09:00-04:00,ATRA,negative
106896.0,45 Healthcare Stocks Moving In Monday's After-Market Session,2019-07-30 04:54:00-04:00,ATRA,neutral
106897.0,Stocks That Managed to Breach 52-Week Lows Friday,2019-07-26 15:45:00-04:00,ATRA,negative
106898.0,"The Daily Biotech Pulse: Obseva Gets The Greenlight, Verastem Climbs On Licensing Deal, Merit Medical Earnings Disappoint",2019-07-26 07:26:00-04:00,ATRA,neutral
106899.0,Atara Biotherapeutics Prices Public 6.8M Share Offering of Common Stock @$15.28/Share,2019-07-19 03:59:00-04:00,ATRA,positive
106900.0,Atara Biotherapeutics shares are trading lower after the company reported a $125 million common stock offering.,2019-07-18 16:07:00-04:00,ATRA,neutral
106901.0,Atara Biotherapeutics Reports $125M Common Stock Offering,2019-07-18 16:04:00-04:00,ATRA,neutral
106902.0,58 Biggest Movers From Yesterday,2019-07-17 04:59:00-04:00,ATRA,neutral
106903.0,41 Stocks Moving In Tuesday's Mid-Day Session,2019-07-16 12:10:00-04:00,ATRA,neutral
106904.0,Atara Biotherapeutics Announces Plan To Initiate Tab-cel FDA Biologics License Application Submission Next Year,2019-07-16 07:03:00-04:00,ATRA,neutral
106905.0,"The Daily Biotech Pulse: Neurocrine's Parkinson's Drug Accepted For Review, Sunesis Offering, No Headaches For Biohaven's Migraine Drug",2019-07-11 06:17:00-04:00,ATRA,neutral
106906.0,"The Daily Biotech Pulse: Roche Presents Positive Hemlibra Data, Amgen's Tender Offer For Nuevolution Complete, Genmab Offering",2019-07-09 07:11:00-04:00,ATRA,positive
106907.0,Atara Biotherapeutics Presents Initial ATA188 Phase 1 Safety Results for Patients with Progressive MS at #EAN2019,2019-06-30 19:20:00-04:00,ATRA,positive
106908.0,"The Daily Biotech Pulse: Verrica Rallies, Aclaris Flunked Hair Loss Study, 3 Biotechs To IPO",2019-06-27 07:26:00-04:00,ATRA,negative
106909.0,"The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart",2019-06-26 07:19:00-04:00,ATRA,neutral
106910.0,Atara Biotherapeutics Intends To Provide Update Related To Ongoing Discussions With FDA Regarding Development Of Tab-Cel,2019-06-05 06:16:00-04:00,ATRA,neutral
106911.0,Atara Biotherapeutics Reports Collaborators At Memorial Sloan Kettering Cancer Center Presented Updated Results From Ongoing MSK Phase 1 Study Of Mesothelin-Targeted CAR T Immunotherapy,2019-06-04 09:39:00-04:00,ATRA,negative
106912.0,"Benzinga's Top Upgrades, Downgrades For June 4, 2019",2019-06-04 09:10:00-04:00,ATRA,positive
106913.0,"The Daily Biotech Pulse: ASCO Presentations From Roche, Celgene & More, Edwards Recommends Rejection Of Mini-Tender Offer",2019-06-04 07:45:00-04:00,ATRA,negative
106914.0,Citigroup Upgrades Atara Biotherapeutics to Neutral,2019-06-04 06:22:00-04:00,ATRA,neutral
106915.0,Atara Biotherapeutics Presents Tab-cel Clinical Biomarker Results and Nasopharyngeal Carcinoma Study Design at #ASCO19,2019-06-01 14:33:00-04:00,ATRA,neutral
106916.0,The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace,2019-06-01 11:37:00-04:00,ATRA,neutral
106917.0,"Benzinga's Top Upgrades, Downgrades For May 30, 2019",2019-05-30 08:55:00-04:00,ATRA,positive
106918.0,"Roth Capital Initiates Coverage On Atara Biotherapeutics with Buy Rating, Announces $30 Price Target",2019-05-30 08:00:00-04:00,ATRA,neutral
106919.0,"Stifel Nicolaus Initiates Coverage On Atara Biotherapeutics, Inc. - Common Stock with Buy Rating, Announces $41 Price Target",2019-05-23 08:41:00-04:00,ATRA,neutral
106920.0,"The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular's Glaucoma Trial Fails",2019-05-21 07:40:00-04:00,ATRA,negative
106921.0,"Atara Biotherapeutics Highlights Presentation Of Tab-celÂ®, Mesothelin-Targeted CAR T Clinical Results at American Society of Clinical Oncology",2019-05-15 17:07:00-04:00,ATRA,neutral
106922.0,"The Daily Biotech Pulse: Further Delay in Roche's Spark Acquisition, FDA Nod For Regeneron, Solid Biosciences Sinks On Earnings",2019-05-14 07:42:00-04:00,ATRA,positive
106923.0,"The Daily Biotech Pulse: FibroGen Kidney Disease Trial Disappoints, Medtronic To Buy Titan Spine, Puma's Weak Breast Cancer Drug Sales",2019-05-10 08:00:00-04:00,ATRA,negative
106924.0,82 Biggest Movers From Yesterday,2019-05-10 06:27:00-04:00,ATRA,neutral
106925.0,71 Stocks Moving In Thursday's Mid-Day Session,2019-05-09 12:11:00-04:00,ATRA,neutral
106926.0,Atara Biotherapeutics Q1 EPS $(1.44) Beats $(1.51) Estimate,2019-05-09 08:22:00-04:00,ATRA,neutral
106927.0,"The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut",2019-05-09 07:56:00-04:00,ATRA,neutral
106928.0,Shares of several healthcare companies are trading lower on continued weakness over concerns of 'Medicare for all' support within 2020 presidential candidates and the uncertainty over healthcare policy going into the election.,2019-04-18 10:42:00-04:00,ATRA,negative
106929.0,Shares of several healthcare companies are trading lower after Trump renewed his efforts to repeal and replace the Affordable Care Act; the Department of Justice moved to accelerate the appeal process in hopes to invalidate the ACA as unconstitutional.,2019-04-17 10:38:00-04:00,ATRA,positive
106930.0,Atara Biotherapeutics Option Alert: Jun 21 $45 Calls at the Ask: 2000 @ $2.701 vs 2031 OI; Earnings 5/7 Before Open [est] Ref=$37.98,2019-04-09 12:41:00-04:00,ATRA,positive
106931.0,Atara Biotherapeutics Announces Memorial Sloan Kettering Cancer Center Presented Positive Phase 1 Clinical Results for a Mesothelin-Targeted CAR T Immunotherapy in Patients with Advanced Mesothelioma at #AACR2019,2019-03-31 11:17:00-04:00,ATRA,positive
106932.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs",2019-03-30 09:32:00-04:00,ATRA,neutral
106933.0,72 Biggest Movers From Yesterday,2019-02-27 04:55:00-05:00,ATRA,neutral
106934.0,54 Stocks Moving In Tuesday's Mid-Day Session,2019-02-26 12:18:00-05:00,ATRA,neutral
106935.0,"Atara Biotherapeutics, Inc. - Common Stock Q4 EPS $(1.75) Misses $(1.31) Estimate",2019-02-26 07:57:00-05:00,ATRA,negative
106936.0,"Benzinga's Top Upgrades, Downgrades For January 23, 2019",2019-01-23 09:14:00-05:00,ATRA,positive
106937.0,"Mizuho Initiates Coverage On Atara Biotherapeutics with Buy Rating, Announces $62 Price Target",2019-01-23 06:56:00-05:00,ATRA,neutral
106938.0,58 Biggest Movers From Yesterday,2019-01-04 05:35:00-05:00,ATRA,neutral
106939.0,44 Stocks Moving In Thursday's Mid-Day Session,2019-01-03 12:27:00-05:00,ATRA,neutral
106940.0,Atara Biotherapeutics shares are trading lower after the company announced that CEO Isaac Ciechanover plans to step down.,2019-01-03 10:46:00-05:00,ATRA,neutral
106941.0,"Atara Biotherapeutics Reports Pres, CEO Isaac Ciechanover To Step Down; Co. Has Initiated Search To Find Replacement",2019-01-03 07:43:00-05:00,ATRA,neutral
106942.0,Atara Biotherapeutics Reports Exclusivity On License For Mesothelin-Targeted CAR T Immunotherapy For Solid Tumors,2019-01-03 07:36:00-05:00,ATRA,positive
106943.0,Atara Biotherapeutics Exclusively Licenses Mesothelin-Targeted CAR T Immunotherapy For Solid Tumors,2019-01-03 07:35:00-05:00,ATRA,positive
106944.0,Atara Biotherapeutics Presents Positive Efficacy and Safety Results for Patients with Epstein-Barr Virus-Associated Leiomyosarcoma at EMSO 2018,2018-12-15 09:52:00-05:00,ATRA,positive
106945.0,Atara Biotherapeutics Announces Next-Generation CAR T Discoveries and Positive T-Cell Immunotherapy Results in Patients with EBV+ PTLD Involving the CNS at ASH 2018,2018-12-04 04:55:00-05:00,ATRA,positive
106946.0,"The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs",2018-12-02 17:51:00-05:00,ATRA,neutral
106947.0,"Atara Biotherapeutics Announces Publication of Phase 1 Study Demonstrating Clinical Improvement in Progressive Multiple Sclerosis Patients Treated with ATA190, an Autologous Epstein-Barr Virus Immunotherapy",2018-11-19 08:32:00-05:00,ATRA,positive
106948.0,Atara Biotherapeutics Q3 EPS $(1.29) Misses $(1.13) Estimate,2018-11-06 07:56:00-05:00,ATRA,negative
106949.0,"Atara Biotherapeutics Announces Presentations Highlighting Allogeneic T-Cell Immunotherapy Pipeline And CAR T Technologies At The 60th American Society of Hematology (ASH) Annual Meeting And European Society for Medical Oncology, Dec 13-16",2018-11-01 09:04:00-04:00,ATRA,neutral
106950.0,Atara Biotherapeutics Reports Strategic Collaboration With Moffitt Cancer Center For Development Of Next-Gen CAR T Immunotherapies,2018-09-06 07:30:00-04:00,ATRA,negative
106951.0,Atara Biotherapeutics Q2 EPS $(1.15) Down From $(0.94) YoY,2018-08-01 08:11:00-04:00,ATRA,neutral
106952.0,"Atara Biotherapeutics Opens Operations and Manufacturing Facility In Thousand Oaks, CA",2018-06-25 08:15:00-04:00,ATRA,neutral
106953.0,Atara Biotherapeutics Announces Tab-cel Achieves Positive Long-Term Outcomes in Phase 2 Studies of Patients with Epstein-Barr Virus Associated Post-Transplant Lymphomas at #EHA2018,2018-06-15 04:43:00-04:00,ATRA,positive
106954.0,"Benzinga's Daily Biotech Pulse: Melinta, Ardelyx Pull Back On Offerings, Insys Awaits FDA Verdict",2018-05-22 08:05:00-04:00,ATRA,positive
106955.0,Atara Biotherapeutics Reports Expansion Of Collaboration With Memorial Sloan Kettering Cancer Center To Develop Next Gen Of Genetically Engineered Chimeric Antigen Receptor T-Cell Immunotherapies,2018-05-08 07:40:00-04:00,ATRA,negative
106956.0,Atara Biotherapeutics Q1 EPS $(1.05) Misses $(0.92) Estimate,2018-05-08 07:09:00-04:00,ATRA,negative
106957.0,"JP Morgan Initiates Coverage On Atara Biotherapeutics with Overweight Rating, Announces $56.00 Price Target",2018-04-10 09:18:00-04:00,ATRA,neutral
106958.0,Guggenheim Initiates Coverage On Atara Biotherapeutics with Neutral Rating,2018-03-16 10:20:00-04:00,ATRA,neutral
106959.0,45 Biggest Movers From Yesterday,2018-03-14 04:55:00-04:00,ATRA,neutral
106960.0,Atara Biotherapeutics Reports Pricing OF ~4.286M Share Offering At $35/Share,2018-03-01 06:08:00-05:00,ATRA,positive
106961.0,"Benzinga's Top Upgrades, Downgrades For February 28, 2018",2018-02-28 09:11:00-05:00,ATRA,positive
106962.0,JMP Securities Downgrades Atara Biotherapeutics to Market Perform,2018-02-28 07:59:00-05:00,ATRA,positive
106963.0,Atara Biotherapeutics Reports Offering Of $150M In Common Shares,2018-02-27 16:45:00-05:00,ATRA,positive
106964.0,"Atara Biotherapeutics Filing Shows Registration For Mixed Securities Shelf Offering, No Amount Disclosed",2018-02-27 15:59:00-05:00,ATRA,neutral
106965.0,"Atara Biotherapeutics Reports Q4 EPS $(1.15) vs $(1.14) Est., No Sales",2018-02-27 07:13:00-05:00,ATRA,negative
106966.0,Atara Biotherapeutics CFO To Retire In April 2018,2018-02-21 16:57:00-05:00,ATRA,neutral
106967.0,40 Stocks Moving In Thursday's Mid-Day Session,2018-02-15 12:11:00-05:00,ATRA,neutral
106968.0,"Benzinga's Top Upgrades, Downgrades For February 15, 2018",2018-02-15 10:24:00-05:00,ATRA,positive
106969.0,Citigroup Downgrades Atara Biotherapeutics Inc to Sell,2018-02-15 09:42:00-05:00,ATRA,neutral
106970.0,22 Stocks Moving In Thursday's Pre-Market Session,2018-02-15 08:41:00-05:00,ATRA,neutral
106971.0,40 Biggest Movers From Yesterday,2018-02-14 04:56:00-05:00,ATRA,neutral
106972.0,32 Stocks Moving In Monday's Mid-Day Session,2018-02-12 12:20:00-05:00,ATRA,neutral
106973.0,40 Biggest Movers From Friday,2018-02-05 04:28:00-05:00,ATRA,neutral
106974.0,35 Stocks Moving In Friday's Mid-Day Session,2018-02-02 12:22:00-05:00,ATRA,neutral
106975.0,45 Biggest Movers From Friday,2018-01-29 04:17:00-05:00,ATRA,neutral
106976.0,41 Stocks Moving In Friday's Mid-Day Session,2018-01-26 13:04:00-05:00,ATRA,neutral
106977.0,"Benzinga's Top Upgrades, Downgrades For January 26, 2018",2018-01-26 09:14:00-05:00,ATRA,positive
106978.0,Cowen & Co. Initiates Coverage On Atara Biotherapeutics with Outperform Rating,2018-01-26 08:00:00-05:00,ATRA,neutral
106979.0,26 Stocks Moving In Thursday's Pre-Market Session,2018-01-25 08:06:00-05:00,ATRA,neutral
106980.0,38 Biggest Movers From Friday,2018-01-16 05:26:00-05:00,ATRA,neutral
106981.0,33 Stocks Moving In Friday's Mid-Day Session,2018-01-12 12:25:00-05:00,ATRA,neutral
106982.0,Atara Biotherapeutics Reports FDA Clearance To Proceed with Enrollment at U.S. Sites for Ongoing Global Phase 1 Clinical Study to Evaluate ATA188 in Patients with Progressive or Relapsing-Remitting Multiple Sclerosis,2018-01-10 08:03:00-05:00,ATRA,neutral
106983.0,"Atara Biotherapeutics 13G Filing From Camber Capital Shows Raised Stake From ~535.5K Shares At End Of Last Qtr. To 2.5M Shares, Or 6.65% Stake",2018-01-05 11:17:00-05:00,ATRA,positive
106984.0,Atara Biotherapeutics Prices 7M Share Offering @$18.25/Share,2018-01-04 04:06:00-05:00,ATRA,positive
106985.0,Mid-Afternoon Market Update: Crude Oil Up 2%; Moneygram Shares Plummet,2018-01-03 14:32:00-05:00,ATRA,negative
106986.0,30 Stocks Moving In Wednesday's Mid-Day Session,2018-01-03 12:26:00-05:00,ATRA,neutral
106987.0,Mid-Day Market Update: SCANA Climbs Following Merger With Dominion Energy; Crispr Therapeutics Shares Slide,2018-01-03 12:16:00-05:00,ATRA,positive
106988.0,Mid-Morning Market Update: Markets Open Higher; Commercial Metals Profit Beats Estimates,2018-01-03 10:18:00-05:00,ATRA,positive
106989.0,Citigroup Upgrades Atara Biotherapeutics to Neutral,2018-01-03 09:17:00-05:00,ATRA,neutral
106990.0,25 Stocks Moving In Wednesday's Pre-Market Session,2018-01-03 08:08:00-05:00,ATRA,neutral
106991.0,Atara Biotherapeutics Reports Offering Of $100M In Common Stock,2018-01-02 16:01:00-05:00,ATRA,neutral
106992.0,26 Biggest Movers From Friday,2018-01-02 04:43:00-05:00,ATRA,neutral
106993.0,Mid-Afternoon Market Update: Crude Oil Up 1%; Pareteum Shares Spike Higher,2017-12-29 14:54:00-05:00,ATRA,negative
106994.0,26 Stocks Moving In Friday's Mid-Day Session,2017-12-29 12:36:00-05:00,ATRA,neutral
106995.0,Mid-Day Market Update: ADTRAN Drops On Weak Q4 Guidance; Atara Biotherapeutics Shares Spike Higher,2017-12-29 12:15:00-05:00,ATRA,negative
106996.0,UPDATE: Jefferies On Atara Says 'We would Buy the stock',2017-12-29 11:48:00-05:00,ATRA,neutral
106997.0,"Jefferies Comments On Atara Biotherapeutics (Shares Up 20% Fri.) In Mid-Day Note, Says 'Overhang Removed With Start of Phase III Trials...Full Speed Ahead'; Maintains Buy Rating, $30 Price Target",2017-12-29 11:48:00-05:00,ATRA,neutral
106998.0,Mid-Morning Market Update: Markets Edge Lower; MassRoots Is Going To Leverage Blockchain For The Cannabis Industry,2017-12-29 10:11:00-05:00,ATRA,negative
106999.0,Atara Biotherapeutics Announces FDA Clearance to Initiate Two Phase 3 Clinical Studies to Evaluate Tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder,2017-12-29 06:01:00-05:00,ATRA,negative
107000.0,UPDATE: Atara Says Expects To Initiate Phase 2 Studies With Tabelecleucel By End Of 2017,2017-12-11 10:02:00-05:00,ATRA,neutral
107001.0,UPDATE: Atara Says Multicenter Clinical Findings In Patients With EBV+PTLD Consistent With Tabelecleucel Profile Observed In Phase 2 Studies,2017-12-11 10:02:00-05:00,ATRA,neutral
107002.0,Atara Biotherapeutics Reports Updated Interim Results From Multicenter Expanded Access Study Of Tabelecleucel In Patients With Rituximab-Refractory EBV Associated PTLD At ASH,2017-12-11 10:01:00-05:00,ATRA,neutral
107003.0,Atara Biotherapeutics Reports Q3 EPS $(1.02) vs $(0.98) Est.,2017-11-09 08:04:00-05:00,ATRA,neutral
107004.0,Atara Biotherpeutics Reports Received Rare Pediatric Disease Designation From FDA For ATA230 For Treatment Of CMV Infection,2017-10-26 08:16:00-04:00,ATRA,neutral
107005.0,Atara Biotherapeutics Receives Rare Pediatric Disease Designation from FDA for ATA230,2017-10-26 08:07:00-04:00,ATRA,neutral
107006.0,Atara Biotherapeutics Reports 6 Of 10  Progressive MS Patients Experienced Clinical Improvements In Ongoing Phase 1 Study Of ATA190,2017-10-25 08:15:00-04:00,ATRA,positive
107007.0,Atara Biotherapeutics Announces Six of Ten Progressive Multiple Sclerosis Patients Experienced Clinical Improvements in an Ongoing Phase 1 Study of Autologous ATA190,2017-10-25 08:08:00-04:00,ATRA,positive
107008.0,"Atara Biotherapeutics Begins 60 Patient, Global Phase 1 Clinical Study to Evaluate Allogeneic ATA18",2017-10-19 08:02:00-04:00,ATRA,neutral
107009.0,Atara Biotherapeutics Receives 'Positive' Health Canada Regulatory Feedback for ATA129,2017-09-11 08:11:00-04:00,ATRA,neutral
107010.0,Atara Biotherapeutics Reports Q2 EPS $(0.94) vs $(0.89) Est.,2017-08-07 17:14:00-04:00,ATRA,neutral
107011.0,6 Biotech Stocks Jefferies Says Are Undervalued,2017-06-23 09:21:00-04:00,ATRA,neutral
107012.0,Atara Bio Partners With Merck To Evaluate KEYTRUDA In Combination With ATA129 In NPC,2017-04-21 08:03:00-04:00,ATRA,neutral
107013.0,"Atara Bio Reports Interim Results from Ongoing Phase 1 Trial, Says Encouraging Clinical Improvements Correlate With EBV Reactivity",2017-04-20 16:21:00-04:00,ATRA,positive
107014.0,Atara Biotherapeutics Reports $75M Stock Offering,2017-03-27 17:28:00-04:00,ATRA,neutral
107015.0,Atara Bio Reports Q4 EPS $(0.63) vs. $(0.75) YoY,2017-03-09 08:08:00-05:00,ATRA,neutral
107016.0,Atara Bio Says Planning to Submit Conditional Marketing Application in 2018,2017-01-03 08:04:00-05:00,ATRA,neutral
107017.0,10 Biggest Mid-Day Gainers For Tuesday,2016-12-13 12:42:00-05:00,ATRA,neutral
107018.0,"Atara Bio Reaches Agreement with FDA on Design of Phase 3 Trials for its Lead Anti-Cancer Immunotherapy Program, With Primary Endpoint Of MATCH And ALLELE Trials Being Objective Response Rate",2016-12-12 08:04:00-05:00,ATRA,positive
107019.0,Atara Bio Announces Results from Ongoing Phase 2 Trial of Allogeneic Cytomegalovirus-specific Cytotoxic T Lymphocytes at ASH 2016,2016-12-03 14:51:00-05:00,ATRA,neutral
107020.0,Atara Bio Reports Q3 EPS $(0.78) vs. Est. $(0.88),2016-11-04 08:02:00-04:00,ATRA,neutral
107021.0,4 Stocks That Rallied Three Days On Increasing Volume,2016-11-04 07:17:00-04:00,ATRA,neutral
107022.0,15 Stocks Moving In Tuesday's Pre-Market Session,2016-11-01 08:32:00-04:00,ATRA,neutral
107023.0,15 Stocks Which Plummeted Three Days On Increasing Volume,2016-10-27 07:25:00-04:00,ATRA,neutral
107024.0,"Jefferies Assumes Atara Biotherapeutics, Inc. - Common Stock at Buy",2016-10-24 06:45:00-04:00,ATRA,neutral
107025.0,Atara Bio Granted Access to Priority Medicines Regulatory Support for Allogeneic Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes for Treatment of EBV-Associated Post Transplant Lymphoproliferative Disorder,2016-10-18 08:02:00-04:00,ATRA,positive
107026.0,Atara Bio Receives Positive Opinion from EMA on Orphan Drug Designation for Allogeneic Cytomegalovirus (CMV)-specific Cytotoxic T Lymphocytes (CTL) for Treatment of CMV Infection in Patients with Impaired Immune Systems,2016-10-11 08:06:00-04:00,ATRA,positive
107027.0,15 Biggest  Mid-Day Losers For Thursday,2016-09-15 16:36:00-04:00,ATRA,negative
107028.0,7 Biggest Price Target Changes For Thursday,2016-09-15 10:07:00-04:00,ATRA,neutral
107029.0,Benzinga's Top Downgrades,2016-09-15 08:57:00-04:00,ATRA,positive
107030.0,Atara Biotherapeutics Has 25% Downside,2016-09-15 07:56:00-04:00,ATRA,negative
107031.0,"Goldman Sachs Downgrades Atara Biotherapeutics to Sell, Lowers PT to $16.00",2016-09-15 06:02:00-04:00,ATRA,negative
107032.0,A Handful of Biotech Stocks Plunge After Disappointing Results,2016-08-08 16:51:00-04:00,ATRA,negative
107033.0,12 Biggest Mid-Day Losers For Monday,2016-08-08 13:07:00-04:00,ATRA,negative
107034.0,Atara Bio Reports Q2 EPS $(0.66) vs. Est. $(0.61),2016-08-08 08:03:00-04:00,ATRA,neutral
107035.0,"Atara Biotherapeutics Reports First Patient Dosing in Multi-Center Expanded Access Protocol for Study of EBV-CTLs in EBV-Associated Lymphomas, Lymphoproliferative Disorders",2016-07-12 08:02:00-04:00,ATRA,neutral
107036.0,Atara Bio Receives Advanced Therapy Medicinal Product Classification for Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes (EBV-CTLs) from EMA,2016-06-23 09:33:00-04:00,ATRA,positive
107037.0,Atara Bio Announces Clinical Trial Results for Treatment of EBV+ Nasopharyngeal Carcinoma using Allogeneic Epstein-Barr Virus Cytotoxic T-Lymphocyte Product Candidate,2016-06-07 04:43:00-04:00,ATRA,neutral
107038.0,Atara Bio Reports Q1 EPS $(0.58) vs $(0.55) Est.,2016-05-05 08:14:00-04:00,ATRA,neutral
107039.0,Atara Bio's Partner QIMR Berghofer Medical Research Report Positive Clinical Data For T-Cell Immunotherapy In INPC,2016-04-19 17:16:00-04:00,ATRA,positive
107040.0,Atara Bio Receives EMA Orphan Drug Designation for Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes to Treat Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorder,2016-03-23 09:19:00-04:00,ATRA,neutral
107041.0,Atara Bio Announces Collaborating Investigators to Present Data from a Late Breaking Abstract at the (AACR) Annual Meeting,2016-03-16 16:45:00-04:00,ATRA,neutral
107042.0,Atata Bio Reports Q4 EPS $(0.75) vs. Est. $(0.48),2016-03-03 16:16:00-05:00,ATRA,neutral
107043.0,Atara Bio Receives FDA Orphan Drug Designation for EBV-CTL to Treat Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorder,2016-02-08 08:00:00-05:00,ATRA,neutral
107044.0,"China Finance Online, Heartland Payment Systems Lead Tuesday's After-Hours Movers",2015-12-15 17:15:00-05:00,ATRA,neutral
107045.0,"Citigroup Downgrades Atara Biotherapeutics to Sell, Lowers PT to $16.00",2015-12-15 06:41:00-05:00,ATRA,negative
107046.0,Mid-Afternoon Market Update: Crude Oil Rises Over 2%; GoPro Shares Decline Following Morgan Stanley Downgrade,2015-12-14 15:01:00-05:00,ATRA,negative
107047.0,Mid-Day Market Update: Trina Solar Surges Following Announcement of Going Private Proposal; Newell Rubbermaid Shares Slip,2015-12-14 12:33:00-05:00,ATRA,positive
107048.0,Mid-Morning Market Update: Markets Mostly Flat; Newell Rubbermaid To Buy Jarden,2015-12-14 09:57:00-05:00,ATRA,neutral
107049.0,Benzinga's Top #PreMarket Losers,2015-12-14 08:22:00-05:00,ATRA,negative
107050.0,Atara Bio Announces Positive Results From a Phase 2 Clinical Trial of Cytomegalovirus Targeted Cytotoxic T Lymphocytes (CMV-CTL),2015-12-06 09:11:00-05:00,ATRA,positive
107051.0,Atara Bio Announces Positive Results From Phase 1 Clinical Trial of Wilms' Tumor 1 Targeted Cytotoxic T Lymphocytes (WT1-CTL) Product Candidate in Hematologic Malignancies,2015-12-05 12:01:00-05:00,ATRA,positive
107052.0,"Goldman Sachs Assumes Atara Biotherapeutics at Neutral, Announces $38.00 PT",2015-11-18 06:51:00-05:00,ATRA,neutral
107053.0,Atara Biotherapeutics and QIMR Berghofer Medical Research Institute Announce Exclusive License and Research Agreements,2015-10-21 06:32:00-04:00,ATRA,positive
107054.0,Atara Bio Receives FDA Orphan Drug Designation for STM 434 for Ovarian Cancer,2015-10-20 06:40:00-04:00,ATRA,negative
107055.0,Atara Bio's PINTA 745 Improves Insulin Sensitivity and Alters Fat Metabolism in Mice Fed With a High Fat Diet,2015-10-05 07:00:00-04:00,ATRA,positive
107056.0,Atara Bio's T-Cell Product Candidate Activated Against Wilms' Tumor 1 Protein Demonstrates Encouraging Results in Patients With Plasma Cell Leukemia,2015-09-24 06:31:00-04:00,ATRA,positive
107057.0,Benzinga's Top Initiations,2015-09-09 09:35:00-04:00,ATRA,positive
107058.0,"Buy Atara's T-Cell Potential, Stock Could Nearly Double: Canaccord",2015-09-09 09:04:00-04:00,ATRA,neutral
107059.0,US Stock Futures Signal Lower Start On Wall Street,2015-08-31 07:01:00-04:00,ATRA,negative
107060.0,Atara Biotherapeutics Announces Completion of Enrollment in PINTA 745 Phase 2 Clinical Trial in End-Stage Renal Disease Patients With Protein Energy Wasting,2015-08-31 06:31:00-04:00,ATRA,negative
107061.0,Atara Biotherapeutics Reports Q2 Loss $0.62 Vs Est Loss $0.44,2015-08-06 06:38:00-04:00,ATRA,negative
107062.0,Mid-Morning Market Update: Markets Surge; PriceSmart Posts Mixed Results,2015-07-10 11:35:00-04:00,ATRA,neutral
107063.0,Morning Market Losers,2015-07-10 09:54:00-04:00,ATRA,negative
107064.0,Benzinga's Top #PreMarket Losers,2015-07-10 08:19:00-04:00,ATRA,negative
107065.0,US Stock Futures Surge Ahead Of Wholesale Inventories Report,2015-07-10 07:36:00-04:00,ATRA,neutral
107066.0,Atara Bio Prices ~3.46M Share Offering @$52.00/Share,2015-07-10 04:24:00-04:00,ATRA,positive
107067.0,Amended S-1 from Atara Biotherapeutics Shows Increased Initial Value from $125M to $172.5M,2015-07-09 10:24:00-04:00,ATRA,positive
107068.0,Atara Bio Announces $125M Secondary Offering,2015-07-07 16:06:00-04:00,ATRA,neutral
107069.0,Atara Biotherapeutics Exercises Exclusive License to T-Cell Technology From Memorial Sloan Kettering Cancer Center,2015-06-15 06:31:00-04:00,ATRA,negative
107070.0,7 Biotech Stocks Moving Off The UBS Healthcare Conference,2015-05-19 14:16:00-04:00,ATRA,neutral
107071.0,Atara Biotherapeutics Reports Q1 Loss $0.42 Vs Est Loss $0.44,2015-05-07 16:19:00-04:00,ATRA,negative
107072.0,EBV-CTL Clinical Trial Data Presented by Atara Biotherapeutics' Collaborating Investigators at a Plenary Session at the American Association for Cancer Research Annual Meeting 2015,2015-04-20 06:38:00-04:00,ATRA,negative
107073.0,Atara Biotherapeutics' Collaborating Investigators' Abstract on T-Cell Therapy for EBV Lymphoma to be Presented at Clinical Trials Plenary Session at AACR Annual Meeting,2015-04-19 13:04:00-04:00,ATRA,neutral
107074.0,13G Filing From Baupost Group Reports An Increased Stake In Atara Biotherapeutics From 10.25% To 19.6%,2015-04-09 17:13:00-04:00,ATRA,positive
107075.0,"Amgen Reports 6% Passive Stake in Atara Biotherapeutics as of Oct 16, 2014",2015-04-01 06:14:00-04:00,ATRA,positive
107076.0,Atara Reports FDA Grants Breakthrough Therapy Designation to EBV Targeted T-Cells for Treatment of EBV-LPD,2015-03-02 06:32:00-05:00,ATRA,positive
107077.0,Atara Bio Prices $65.5M Offering of Common Stock,2015-02-12 08:00:00-05:00,ATRA,neutral
107078.0,Atara Bio Reports Offering of 3M Common Shares,2015-02-09 16:03:00-05:00,ATRA,positive
107079.0,Atara Biotherapeutics Reports Q3 EPS of $(4.20),2014-11-12 06:01:00-05:00,ATRA,neutral
107080.0,UPDATE: Citigroup Initiates Coverage On Atara Biotherapeutics On New Lead Product Candidates,2014-11-10 10:58:00-05:00,ATRA,neutral
107081.0,Benzinga's Top Initiations,2014-11-10 09:04:00-05:00,ATRA,positive
107082.0,"Citigroup Initiates Coverage on Atara Biotherapeutics at Buy, Announces $37.00 PT",2014-11-10 08:49:00-05:00,ATRA,neutral
107083.0,Jefferies Initiates Atara Biotherapeutics At Buy,2014-11-10 08:39:00-05:00,ATRA,neutral
107084.0,"Jefferies Initiates Coverage on Atara Biotherapeutics at Buy, Announces $35.00 PT",2014-11-10 05:35:00-05:00,ATRA,neutral
107085.0,"Goldman Sachs Initiates Coverage on Atara Biotherapeutics at Neutral, Announces $30.00 PT",2014-11-10 05:31:00-05:00,ATRA,neutral
107086.0,"IPO for Atara Biotherapeutics Opens at $9.89, IPO Priced at $11/Share",2014-10-16 10:37:00-04:00,ATRA,neutral
107087.0,Expected IPOs For October 16,2014-10-16 09:09:00-04:00,ATRA,neutral
107088.0,Atara Biotherapeutics Prices 5M Share IPO @$11.00/Share,2014-10-16 05:03:00-04:00,ATRA,positive
107089.0,"IPO Lookout: Lots of Action This Week, But Is Anything A Worthwhile Investment?",2014-07-21 16:37:00-04:00,ATRA,positive
107090.0,Atara Biotherepeutics Prices 5M Share IPO From $14 to $16,2014-07-10 16:46:00-04:00,ATRA,positive
107091.0,Atara Biotherapeutics Files Up to $50M IPO,2014-06-20 15:46:00-04:00,ATRA,neutral
